

April 8, 2015

Dear Manufacturers,

On behalf of INTEGRIS South Oklahoma City Hospital Corporation d/b/a INTEGRIS Southwest Medical Center (“ISOHC”), #DSH370106, this letter is written to inform manufacturers that ISOHC recently underwent an audit by the Health Resources and Services Administration (HRSA) in connection with ISOHC’s participation in the 340B Drug Pricing Program (340B Program). As background, ISOHC is a 389-bed hospital located in Oklahoma City, Oklahoma. ISOHC qualified for the 340B Program as a Disproportionate Share Hospital and has participated in the 340B Program since July 1, 2009.

Through the audit process, ISOHC was found to have non-compliance within its 340B Program and is therefore responsible for repayment as a result of findings that it dispensed 340B drugs to ineligible individuals, as prohibited by Section 340B(a)(5)(B) of the PHSA. ISOHC is committed to complying with the 340B Program requirements. It has revised its policies and procedures, is continuing with robust self-auditing process and has engaged an external auditor to review program compliance.

ISOHC has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from ISOHC and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact Georg Lunday, System Administrative Director of Pharmacy, INTEGRIS Health, Inc., 3300 Northwest Expressway, Oklahoma City, Oklahoma, 73112, (405) 949-3039 or georg.lunday@integrisok.com.

Sincerely,

James D. Moore
President, ISOHC